ライフサイエンスコーパス: human serum albumin

1 ter inhibition with a CCD inhibitor (MUXF(3)-human serum albumin).

2 xchange chromatography based purification of human serum albumin.

3 ed from purified bromelain glycopeptides and human serum albumin.

4 lasma and cerebrospinal fluid protein, i.e., human serum albumin.

5 ells loaded with benzylpenicillin coupled to human serum albumin.

6 omplex two-site interaction of warfarin with human serum albumin.

7 ligand to boronic acids, such as lactate and human serum albumin.

8 of fluorescein isothiocyanate (FITC)-tagged human serum albumin.

9 teinylglycine, and beta-mercaptoethanol) and human serum albumin.

10 idoglycan-polysaccharide (PG-APS) or control human serum albumin.

11 in were accomplished using infusions of 25% human serum albumin.

12 em containing a di-lysine motif derived from human serum albumin.

13 eters reckoned from the crystal structure of human serum albumin.

14 ultrafast hydration dynamics of the protein human serum albumin.

15 ne fusion of a single-chain human insulin to human serum albumin.

16 albumin, beta-lactoglobulin, soy protein and human serum albumin.

17 ublished X-ray crystallographic structure of human serum albumin.

18 not significantly reduced in the presence of human serum albumin.

19 hatase, human serum albumin, and recombinant human serum albumin.

20 L, R218M, R222M, H242V, R257M, and wild type human serum albumin.

21 high affinity binding site for bilirubin on human serum albumin.

22 4 enhances drug stability in the presence of human serum albumin.

23 sites stabilizes the native conformation of human serum albumin.

24 no binding between the peptide oligomers and human serum albumin.

25 ligands and transcription factors (TFs) and human serum albumin.

26 for 4 weeks with benzylpenicillin coupled to human serum albumin.

27 tetraacetic acid (3 MBq), and (125)I-labeled human serum albumin (0.25 MBq), multiple blood samples a

28 patient-years for the Eprex formulation with human serum albumin, 1 case per 100,000 patient-years fo

29 ient-years for the Eprex formulation without human serum albumin, 6 per 100,000 patient-years for the

30 onoclonal antibody, IgG2, and the effects of human serum albumin, a major blood protein, on this phas

31 ture for the clinical safety and efficacy of human serum albumin administration to critically ill pat

32 r of skin mast cells, and challenge with DNP-human serum albumin after passive sensitization induced

33 toxicants and toxic electrophiles react with human serum albumin (albumin); however, the chemistry of

34 their monomeric form, can seize copper from human serum albumin, an abundant copper-containing prote

35 The contents of two amide-AGEs in human serum albumin and apolipoprotein A-II were signifi

36 the quantitative and qualitative analysis of human serum albumin and carbonic anhydrase in binary mix

37 n mice passively sensitized to dinitrophenol-human serum albumin and challenged intradermally.

38 mice passively sensitized with dinitrophenol-human serum albumin and challenged intradermally.

39 ime oxidized phospholipid adducts to LDL and human serum albumin and for the detection of glycosylati

40 the compounds displayed extensive binding to human serum albumin and had limited activity in cellular

41 Tryptic digests of human serum albumin and human lung epithelial cell lysat

42 robe is capable of detecting proteins, i.e., human serum albumin and lysozyme, with high specificity

43 tivity toward potential interferents such as human serum albumin and ovalbumin.

44 Human serum albumin and plasma components decreased DNA

45 rmation of radical-derived DMPO spin-trapped human serum albumin and, to a lesser extent, of DMPO-EPO

46 assessed with technetium Tc 99m radiolabeled human serum albumin, and a pharmacokinetic study was per

47 electrically charged macromolecules, such as human serum albumin, and larger neutral macromolecules s

48 process in samples of bovine serum albumin, human serum albumin, and lysozyme.

49 particles) with proteins (human transferrin, human serum albumin, and ovalbumin).

50 tyl-L-tryptophanamide, alkaline phosphatase, human serum albumin, and recombinant human serum albumin

51 for caffeine and L-tryptophan, which bind to human serum albumin, and the antimalarial agent trimetho

52 tol, N-acetylcysteine, captopril, bovine and human serum albumins, and hydrogen sulfide, are reported

53 Using nitrated human serum albumin as a model, we reduced the disulfide

54 Since the introduction of human serum albumin as a plasma expander in the 1940s, c

55 fect outcomes, administration of ultra-clean human serum albumin at protein concentrations equivalent

56 omers, 2,4- and 2,6-toluene diisocyanate, on human serum albumin at varying diisocyanate/protein rati

57 ther non-heme-containing proteins, including human serum albumin, beta-casein, and carbonic anhydrase

58 Human serum albumin binding assays indicated that the re

59 ivities with lipophilicity and the extent of human serum albumin binding is observed within this seri

60 mer peptide, which lies in Subdomain IIIA of human serum albumin, blocks binding of all three antibod

61 Bovine and human serum albumin (BSA and HSA) are globular proteins

62 ravenous anesthetic (propofol) to bovine and human serum albumin (BSA and HSA) using isothermal titra

63 uggests multiple anesthetic binding sites on human serum albumin, but to date, we have only identifie

64 binding affinity between drug molecules and human serum albumin by combining nanoporous anodic alumi

65 ue to the heterogeneous nature of commercial human serum albumin (cHSA), other components, such as th

66 in conjugate, followed by a biotin-galactose-human serum albumin clearing agent and 90Y-dodecane tetr

67 igonucleotides exhibited improved binding to human serum albumin compared to the 2'-O-MOE modified ol

68 y-D-lysine-Le(b) hexasaccharide and an Le(b) human serum albumin conjugate not only inhibited adheren

69 R2 region of gp41, was engineered into a 1:1 human serum albumin conjugate through stable covalent at

70 the tryptic digests of three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

71 We previously reported that diisocyanate-human serum albumin (DIISO-HSA) stimulated production of

72 ella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice.

73 Five-day protocolized regimen of 25 g of human serum albumin every 8 hrs with continuous infusion

74 Chondroitin sulfate and human serum albumin exhibited no significant effects on

75 ocomposites of rare-earth nanomaterials with human serum albumin facilitated systemic biodistribution

76 d we have been investigating the behavior of human serum albumin following exposure to peroxynitrite.

77 The apparent binding affinity of human serum albumin for [(14)C]bilirubin was strongly de

78 ethylenetriamine pentaacetic acid-galactosyl-human serum albumin for evaluation of functional liver v

79 ides because of the high binding affinity of human serum albumin for fatty acids.

80 We have also purified nitrated human serum albumin from an enriched sample of SJL mouse

81 lbumin molecule) in comparison to the plasma human serum albumin from healthy volunteers (22.9 +/- 4.

82 merit are presented for carbonic anhydrase, human serum albumin, gamma-globulins, and thermolysin.

83 ied DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an intermediate mar

84 A new electrochemical biosensor based on the human serum albumin/graphene oxide/3-aminopropyl-trietho

85 decreased binding to hemin, hemoglobin, and human serum albumin-hemin complex.

86 rious proteins such as beta-lactoglobulin A, human serum albumin, hemoglobin, and human carbonic anhy

87 ats injected with PG-PS and 13 injected with human serum albumin (HSA) (control animals).

88 Rabbits receiving human serum albumin (HSA) (controls) were compared with

89 tranasal immunization with LNFPIII linked to human serum albumin (HSA) (HSA-LNFPIII), BALB/c mice mou

90 , or 50 microg/kg/d (n = 2), twice daily, or human serum albumin (HSA) (n = 10).

91 carbons has often been quantified via DNA or human serum albumin (HSA) adducts of the carcinogenic me

92 ts and measured oral clearance using (99m)Tc-human serum albumin (HSA) administered to the oropharynx

93 per, we describe a new modality of measuring human serum albumin (HSA) adsorption continuously on CH3

94 Kd) of individual PFOS and PFOA isomers with human serum albumin (HSA) and (ii) relative binding affi

95 nted with 10% dimethyl sulfoxide (DMSO), 15% human serum albumin (HSA) and 0.1% hyaluronans.

96 )- and (S)-warfarin from the binding protein human serum albumin (HSA) and by performing computer sim

97 on of Re-BFPCA 8a is extended to labeling of human serum albumin (HSA) and Fab fragments under aqueou

98 In the current study, MDI was reacted with human serum albumin (HSA) and hemoglobin (Hb) at molar r

99 0.2 ng/ml to 60 microg/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at

100 analysis by highly abundant proteins such as human serum albumin (HSA) and immunoglobulins (IgGs) whi

101 As model therapeutic proteins, we studied human serum albumin (HSA) and intravenous immunoglobulin

102 C. diphtheriae was also able to use human serum albumin (HSA) and myoglobin (Mb) but not hem

103 hanges of chloride binding to alpha-amylase, human serum albumin (HSA) and Omp32 with pH, and of alph

104 umina rugate filters (NAA-RFs) modified with human serum albumin (HSA) and reflectometric interferenc

105 sing testosterone and its transport proteins human serum albumin (HSA) and sex hormone binding globul

106 In the present study, we used wild-type human serum albumin (HSA) and specific site-directed mut

107 compounds from an NCI compounds library and human serum albumin (HSA) and three known ligands (ibupr

108 hierarchical structure for determination of human serum albumin (HSA) are designed and fabricated.

109 This approach is demonstrated using human serum albumin (HSA) as a model binding agent.

110 ormance affinity chromatography by employing human serum albumin (HSA) as a model protein.

111 re synthesized using the circulatory protein human serum albumin (HSA) as a template, whose synthetic

112 were comparable to glycoconjugates employing human serum albumin (HSA) as the carrier protein.

113 Human serum albumin (HSA) binds 95% of Abeta in blood pl

114 onal isomers are transported to the liver by human serum albumin (HSA) but their precise binding loca

115 ermining binding sites of small molecules on human serum albumin (HSA) by competitive displacement of

116 and highly disulfide-bonded proteins such as human serum albumin (HSA) by online EC reduction of nonr

117 gth of perfluoroalkyl acid (PFAA) binding to human serum albumin (HSA) by use of the protein's native

118 Glycation of human serum albumin (HSA) can also be measured using thi

119 Beside the regulation of fluid distribution, human serum albumin (HSA) carries other activities, such

120 d molecular length among sources and lots of human serum albumin (HSA) commercial preparations intend

121 although the C-terminal domain III (DIII) of human serum albumin (HSA) contains the principal binding

122 ne) surface to the nonspecific adsorption of human serum albumin (HSA) correlated with the degree of

123 munosensor using a simple optical system for human serum albumin (HSA) detection is developed.

124 ting molecularly imprinted polymer (MIP) for human serum albumin (HSA) determination using semi-coval

125 Despite knowing about the location of human serum albumin (HSA) drug binding sites and the res

126 ice received an intraperitoneal injection of human serum albumin (HSA) for alveolar permeability dete

127 ned specifically to enhance interaction with human serum albumin (HSA) for drug delivery.

128 he kinetics and affinities of fibrinogen and human serum albumin (HSA) for TiO2, CeO2, Al2O3 and ZnO

129 to human A2, C1, and C2 domains presented as human serum albumin (HSA) fusion proteins.

130 Conjugation to human serum albumin (HSA) has emerged as a powerful appr

131 umins such as bovine serum albumin (BSA) and human serum albumin (HSA) have found a wide range of bio

132 The model for this work was human serum albumin (HSA) immobilized onto silica by the

133 s, we profiled adducts at the Cys34 locus of human serum albumin (HSA) in 29 nonsmoking Xuanwei and F

134 The label-free detection of human serum albumin (HSA) in aqueous buffer is demonstra

135 MS-325 functions by binding to human serum albumin (HSA) in plasma.

136 s (Dh = 200 nm) which selectively respond to human serum albumin (HSA) in the presence of other thiol

137 jectives of this study were (i) to galactate human serum albumin (HSA) in vitro; (ii) to determine, b

138 we report that binding of retinoate (RA) to human serum albumin (HSA) increases the solid-state elec

139 units, albumin binding data obtained in 4.5% human serum albumin (HSA) indicated that derivatives con

140 The concentration of human serum albumin (HSA) indicates the health state of

141 e-chain variable fragment (scFv) fragment to human serum albumin (HSA) influences pH-dependent bindin

142 Human serum albumin (HSA) interacts with this family of

143 Human serum albumin (HSA) is a natural carrier protein p

144 Human serum albumin (HSA) is a potent inhibitor of Abeta

145 Human serum albumin (HSA) is a versatile transport prote

146 Human serum albumin (HSA) is an abundant plasma protein

147 Human serum albumin (HSA) is an abundant plasma protein

148 Human serum albumin (HSA) is an abundant plasma protein

149 haracterizing how chemical compounds bind to human serum albumin (HSA) is essential in evaluating dru

150 Enhanced nonenzymatic glycosylation (NEG) of human serum albumin (HSA) is observed in diabetic patien

151 pten was detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patient

152 finity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher thera

153 The observed binding with human serum albumin (HSA) of the compounds having C-3 th

154 The effect of human serum albumin (HSA) on an immunokinetic assay for

155 Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl est

156 rats, rats receiving intravitreally injected human serum albumin (HSA) or vascular endothelial growth

157 ions, we loaded ATO onto folate (FA)-labeled human serum albumin (HSA) pretreated with glutathione (G

158 mustard (SM) produces a covalent adduct with human serum albumin (HSA) representing an established pl

159 Trypsin-digested, SDA-cross-linked human serum albumin (HSA) served as a test sample, yield

160 Human serum albumin (HSA) serves as a convenient and eas

161 Human serum albumin (HSA) serves not only as a physiolog

162 In this work, human serum albumin (HSA) stabilized gold nanoclusters (

163 free bilirubin in blood serum samples using human serum albumin (HSA) stabilized gold nanoclusters (

164 ic linkage of dibenzocyclooctyne-derivatized human serum albumin (HSA) through strain-promoted azide-

165 The ability of human serum albumin (HSA) to bind fatty acids (FA) in mu

166 lysis of MS-MS data from mixtures of BSA and human serum albumin (HSA) tryptic digests indicated that

167 tPA was camouflaged with human serum albumin (HSA) via a thrombin-cleavable pepti

168 he serum proteins apotransferrin (apoTf) and human serum albumin (HSA) was addressed as well.

169 A competitive immunoassay for detecting human serum albumin (HSA) was also demonstrated by dosin

170 The affinity of anthocyanins for human serum albumin (HSA) was determined by a fluorescen

171 boxylate (AC) in the chiral binding sites of human serum albumin (HSA) was studied using fluorescence

172 manized variant (huE06 v1.1) in complex with human serum albumin (HSA) were determined at 3- and 2.3-

173 -density-lipoprotein (VLDL) yields 1-3%, and human serum albumin (HSA) yields 0-2%.

174 Human serum albumin (HSA), an abundant component of huma

175 The primary ligands of human serum albumin (HSA), an abundant plasma protein, a

176 Human serum albumin (HSA), an important binding agent fo

177 Human serum albumin (HSA), an important serum competitor

178 of the complex between human FcRn, wild-type human serum albumin (HSA), and a human Fc engineered for

179 f diethylenetriaminepentaacetic acid (DTPA), human serum albumin (HSA), and cysteine.

180 ated for the analysis of carbonic anhydrase, human serum albumin (HSA), and gamma-globulin.

181 article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mains

182 In this work, human serum albumin (HSA), beta-casein, and recombinant

183 Three albumins have been considered, namely human serum albumin (HSA), fatty acid free HSA (ffHSA) a

184 nding interactions of nitric oxide (NO) with human serum albumin (HSA), human hemoglobin A, bovine my

185 wing incubation of aliquots of the sera with human serum albumin (HSA), lipoylated HSA (HSA-LA), PDC-

186 port a method to enrich cysteinyl adducts of human serum albumin (HSA), representing biomarkers of ex

187 ein (human Kallikrein 2) and low response to human serum albumin (HSA), suggesting possible resilienc

188 P) of glucosamine (GlcN) with fibrinogen and human serum albumin (HSA), under simulated physiological

189 time exponential release of a model protein, human serum albumin (HSA), was observed from two differe

190 tein digestion protocols, the model protein, human serum albumin (HSA), was subjected to enzymatic di

191 enous inhibitor of Abeta self-association is human serum albumin (HSA), which binds approximately 90%

192 In this study we examined human serum albumin (HSA), which contained one to nine c

193 Examination of peptides derived from human serum albumin (HSA), which is a protein known to b

194 warfarin during their binding to the protein human serum albumin (HSA), with beta-cyclodextrin being

195 HNE adduction of blood proteins, such as human serum albumin (HSA), yields adducts that may serve

196 eins purified from human lung tissue [with a human serum albumin (HSA)-affinity column] identified th

197 -oxide) prevented such processes by trapping human serum albumin (HSA)-centered radicals, in situ and

198 es CTX, bovine thyroglobulin (Bos d TG), and human serum albumin (HSA)-conjugated alpha-Gal.

199 l library of putative MRI probes targeted to human serum albumin (HSA).

200 was demonstrated by quantitatively detecting human serum albumin (HSA).

201 ng, the alpha(1)-acid-glycoprotein (AGP) and human serum albumin (HSA).

202 covalently bound to apomyoglobin (ApoMg) and human serum albumin (HSA).

203 tational docking with a crystal structure of human serum albumin (HSA).

204 lysis of BPDE adducts from lymphocyte DNA or human serum albumin (HSA).

205 reversibly to cysteine (Cys, position 34) in human serum albumin (HSA).

206 an method was used to study the glycation in human serum albumin (HSA).

207 um or samples containing the binding protein human serum albumin (HSA).

208 n small, focused medicinal libraries against human serum albumin (HSA).

209 A structures with strong binding affinity to human serum albumin (HSA).

210 e binding of drugs to blood proteins such as human serum albumin (HSA).

211 mance affinity monolithic columns containing human serum albumin (HSA).

212 pounds were also found to bind to site II of human serum albumin (HSA).

213 ing of exogenous Co(2+) to the N-terminal of human serum albumin (HSA).

214 to describe the interaction between 2PHE and human serum albumin (HSA).

215 antages of unusually long serum half-life of human serum albumin (HSA).

216 t 50 mM(-1) s(-1) upon binding to Zn(II) and human serum albumin (HSA).

217 deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of in

218 Human serum albumin (HSA, 66.5kDa) was used as a model p

219 studies on the complex between domain III of human serum albumin (HSA-III) and diflunisal, a cyclooxy

220 longation was observed with carrier protein (human serum albumin [HSA] or dextran) alone.

221 egated serum albumin [MAA]) and (99m)Tc-HSA (human serum albumin [HSA]), was assessed.

222 Human serum albumin, HSA, was immobilized onto the surfa

223 One assay used IIIPS mixed with methylated human serum albumin (IIIPS + mHSA) as the coating antige

224 erns were obtained from five serum proteins (human serum albumin, immunoglobulin G, transferrin, fibr

225 to 50 with respect to protein, was added to human serum albumin in buffer at pH 7.2.

226 modulation of aaRS levels to express mutant human serum albumin in excess of 150 mg/L in shake flask

227 ctApoSp) was reduced after immunization with human serum albumin in TLR4(-/-) mice.

228 predominant site of N-homocysteinylation in human serum albumin in vitro and in vivo.

229 ds in lysozyme and all 17 disulfide bonds in human serum albumin, including nested disulfide bonds an

230 50-fold, and physiological concentrations of human serum albumin increased k(2) 220-fold.

231 Human serum albumin inhibited Hb-dependent growth of Hpu

232 Thus, the net lipophilicity and the altered human serum albumin interactions together function to pr

233 Human serum albumin is indicated for the treatment of sh

234 Human serum albumin is modified by methylglyoxal in vivo

235 n (CPO) or diisopropylfluorophosphate (DFP): human serum albumin (K212, K414, K199, and K351), human

236 librium dissociation constant for Zn(2+) and human serum albumin (Kd = (5.62 +/- 0.93) x 10(-7) M) un

237 graphy, with 37-74 MBq of macroaggregates of human serum albumin labeled with technetium 99m.

238 Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/pep

239 d selectivity against other proteins such as human serum albumin, lysozyme and insulin.

240 Tamm-Horsfall protein, chondroitin sulfate, human serum albumin, mixed urinary macromolecules from a

241 We demonstrate here that human serum albumin modified with N(epsilon)-(carboxymet

242 (oxidation of cysteine in position 34 on the human serum albumin molecule) in comparison to the plasm

243 In one example, we show that a recombinant human serum albumin mutant containing a keto amino acid

244 t seen in rabbits injected with 125I-labeled human serum albumin (n=6).

245 more than 95% of model biochemical species (human serum albumin, neurotensin, creatinine, glycine, a

246 the presence of alpha(1) acid glycoprotein, human serum albumin, normal human serum, or fetal bovine

247 ate binding of cis-[Ru(phen)2(ImH)2](2+) and human serum albumin occurs via noncovalent interactions

248 easing amounts of antigen (2,4-dinitrophenyl-human serum albumin or ovalbumin) in the presence of ext

249 The six human serum albumin preparations analyzed contained a hi

250 Commercially available human serum albumin preparations and healthy volunteers.

251 for a large percentage of the composition of human serum albumin preparations used for the treatment

252 Six commercially available human serum albumin preparations were analyzed by high-p

253 erents investigated (NaHS, NH4OH, NaSCN, and human serum albumin) produced a signal that could be int

254 Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradati

255 esonators is demonstrated for the example of human serum albumin protein adsorption from aqueous buff

256 er, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in inc

257 for each of four proteins consisting of BSA, human serum albumin, rabbit IgG, and protein G were dyna

258 Lot-to-lot variability in native human serum albumin ranged between 4.8% and 11.2% in thr

259 Injection of biotinylated galactosyl-human serum albumin reduced the circulating levels of co

260 Some of the myristate binding sites in human serum albumin resemble the maize nsLTP, implying t

261 strong and specific affinity of recombinant human serum albumin (rHSA) towards cholesteryl-modified

262 phytase activity in rice-derived recombinant human serum albumin (rHSA) using a sensitive, label-free

263 fasting volunteers along with radioiodinated human serum albumin (RIHSA).

264 were compared with those receiving S-nitroso human serum albumin (S-NO-HSA) beginning 30 minutes befo

265 present in tobacco smoke, were reacted with human serum albumin (SA) and formed labile sulfenamide o

266 rawn and replaced with an equal volume of 5% human serum albumin-saline mixture) to reduce [Hb] (Low

267 the extracellular domain of EphB4 fused with human serum albumin (sEphB4-HSA).

268 oism spectra of bilirubin bound to the above human serum albumin species in aqueous solutions saturat

269 The following recombinant human serum albumin species were synthesized in the yeas

270 Human serum albumin species with a bound Cys34 account f

271 onformations of bilirubin bound to the above human serum albumin species.

272 dent methods and found to be similar for all human serum albumin species.

273 process and present human serum albumin to a human serum albumin-specific and DR4 allele-restricted T

274 ps (glutamate in antibody 34E4 and lysine in human serum albumin) surrounded by relatively nonpolar g

275 wed higher solubilities and lower binding to human serum albumin than that of Mocetinostat.

276 specific DR4 allele, can process and present human serum albumin to a human serum albumin-specific an

277 he administration of these oxidized forms of human serum albumin to critically ill patients warrants

278 presented for the binding of L-tryptophan to human serum albumin to exemplify the method.

279 xploit the intrinsic transport properties of human serum albumin to tune the blood circulatory half-l

280 Methylglyoxal reacted with human serum albumin under physiological conditions to fo

281 l of antibody 34E4 and an X-ray structure of human serum albumin was accomplished.

282 Human serum albumin was added at a final concentration o

283 Also, for the purpose of comparison, human serum albumin was analyzed in the plasma of health

284 Recombinant human serum albumin was even more striking with lifetime

285 Finally, human serum albumin was found to bind NO2-CLA both non-c

286 herefore, the interaction between KP1019 and human serum albumin was investigated by means of X-ray c

287 In these experiments, human serum albumin was modified in a myeloperoxidase-me

288 When human serum albumin was modified minimally with methylgl

289 Human serum albumin was used as a model protein to detec

290 The interaction of L-tryptophan with human serum albumin was used as a model system to test t

291 Site-directed mutagenesis of human serum albumin was used to study the role of variou

292 human IgE even when human IgG, thrombin, and human serum albumin were present at 100-fold concentrati

293 ng OCT interference from a standard protein, human serum albumin, where all of the unique peaks contr

294 Human serum albumin, which contains a single tryptophan,

295 oci of blood proteins, particularly Cys34 of human serum albumin, which is the dominant scavenger of

296 aRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcgammaR-binding act

297 ly redock perfluorooctanesulfonate (PFOS) to human serum albumin with deviations smaller than 2 A.

298 y occurs as a consequence of the reaction of human serum albumin with homocysteine thiolactone.

299 an antibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all thre

300 I) binds to the multimetal binding site A on human serum albumin with two inner-sphere water ligands